AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.00515-06v1
51/1/379    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Beer, R.
Right arrow Articles by Schmutzhard, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Beer, R.
Right arrow Articles by Schmutzhard, E.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2007, p. 379-382, Vol. 51, No. 1
0066-4804/07/$08.00+0     doi:10.1128/AAC.00515-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Pharmacokinetics of Intravenous Linezolid in Cerebrospinal Fluid and Plasma in Neurointensive Care Patients with Staphylococcal Ventriculitis Associated with External Ventricular Drains{triangledown}

Ronny Beer,1* Klaus W. Engelhardt,1 Bettina Pfausler,1 Gregor Broessner,1 Raimund Helbok,1 Peter Lackner,1 Christian Brenneis,1 Stefan T. Kaehler,2 Apostolos Georgopoulos,3 and Erich Schmutzhard1

Clinical Department of Neurology, Neurological Intensive Care Unit, Innsbruck Medical University,1 Department of Pharmacology and Toxicology, Institute of Pharmacy, Leopold Franzens University of Innsbruck, Innsbruck,2 Department of Medicine I, Division of Infectious Diseases, Medical University of Vienna, Vienna, Austria3

Received 26 April 2006/ Returned for modification 9 August 2006/ Accepted 11 October 2006

The pharmacokinetic profile of linezolid in cerebrospinal fluid (CSF) in five neurointensive care patients with staphylococcal ventriculitis was studied. The mean area under concentration-time curve (± standard deviation) was 63 ± 18.9 mg · h/liter, with a CSF-to-plasma ratio of 0.8 ± 0.3. Times above MIC in CSF were 99.8% and 57.2% for pathogens with MICs of 2 mg/liter and 4 mg/liter, respectively.

* Corresponding author. Mailing address: Innsbruck Medical University, Clinical Department of Neurology, Neurological Intensive Care Unit, Anichstrasse 35, 6020 Innsbruck, Austria. Phone: 0043 (512) 504-27295. Fax: 0043 (512) 504-24288. E-mail: ronny.beer{at}uibk.ac.at.

{triangledown} Published ahead of print on 16 October 2006.

Antimicrobial Agents and Chemotherapy, January 2007, p. 379-382, Vol. 51, No. 1
0066-4804/07/$08.00+0     doi:10.1128/AAC.00515-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.





Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2007 by the American Society for Microbiology. All rights reserved.